Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre
Year: 2025
Type: article
Study design: Observational Study
Abstract: Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations. This retrospective study reviewed the Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) at baseline and 16–20 weeks of 84 consecutive patients who received lebrikizumab subcutaneously at the label dose in a tertiary centre. EASI scores were available at 16–20 weeks for 72 patients. At this timepoint, 80.6% (58/72) achieved EASI 50, 56.9% (41/72) reached EASI 75, and 27.8% (20/72) attained EASI 90. DLQI was reduced by an average of − 1.5 points at 16–20 weeks. No serious adverse events were reported. Ocular adverse events occurred in 21.4% of the cohort (18/84). Eleven out of 14 patients that previously experienced conjunctivitis with dupilumab or tralokinumab had no recurrence with lebrikizumab. In this real-world cohort of patients with atopic dermatitis, lebrikizumab demonstrated efficacy comparable to that observed in clinical trials. It may provide an alternative treatment option for individuals who have discontinued other biologics as a result of conjunctivitis. Atopic dermatitis, also known as eczema, is a long-lasting skin condition that can cause intense itching, redness, and reduced quality of life. Lebrikizumab is a newer injectable medicine for people with moderate to severe eczema. It has shown good results in clinical trials, but there is limited information on how well it works in everyday medical practice. We looked at the medical records of 84 people with eczema who were treated with lebrikizumab at a specialist centre. We checked their skin severity scores and quality-of-life scores before starting treatment and again after 16–20 weeks. Most patients improved with lebrikizumab. A smaller group had near-clear skin. People also reported feeling much better in their daily lives, with large improvements in quality-of-life scores. No serious side effects were seen. Eye-related side effects, such as irritation were noted. Importantly, most people who had previously developed conjunctivitis (eye inflammation) while taking other eczema biologics did not experience this problem again with lebrikizumab. This study suggests that lebrikizumab can be an effective and well-tolerated treatment for eczema outside of clinical trials. It may also be a useful option for people who stopped other biologic treatments because of eye-related side effects.
Source: Dermatology and Therapy
Authors: Azmeralda Abraheem, Neenu Sebastian, Firas C. Kreeshan, Tim H. Clayton, Hamish J. A. Hunter, Richard B. Warren
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $7,400
OpenAlex ID: W4417091116